Page 3 - Early Access Programs News Today

Pherecydes Pharma Obtains €2 Million in Non-dilutive Financing From Bpifrance Regulatory News: Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that it has obtained, within the framework of a "State-Guaranteed Loan Innovation Support", a €2 million loan from Bpifrance, the French public investment bank. This interest-bearing loan benefits from a on...

(0) WILLINGTON, England, April 8, 2021 /PRNewswire/ -- Bionical Emas, a global specialist Clinical Research Organization (CRO) has today announced the launch of a Managed Access Program for Jazz Pharmaceuticals medicinal product JZP-458 for the treatment of patients with Acute Lymphoblastic Leukaemia (ALL) and Lymphoblastic Lymphoma (LBL) following hypersensitivity to E. Coli-derived asparaginases. The Managed Access Program provides a mechanism through which unsolicited physician requests, to ...

CET- Comunicado - ";ultimaHoraHtml += " " + json.lead + "";}ultimaHoraHtml += ""; document.getElementById("urgente").innerHTML = ultimaHoraHtml; } } }); WILLINGTON, England, April 8, 2021 /PRNewswire/ -- Bionical Emas, a global specialist Clinical Research Organization (CRO) has today announced the launch of a Managed Access Program for Jazz Pharmaceuticals medicinal product JZP-458 for the treatment of patients with Acute Lymphoblastic Leukaemia (ALL) an...